Literature DB >> 31342158

Clinical characteristics of autoimmune disorders in the central nervous system associated with myasthenia gravis.

Kimitoshi Kimura1,2,3, Yoichiro Okada1,4, Chihiro Fujii5, Kenichi Komatsu2, Ryosuke Takahashi1, Sadayuki Matsumoto2, Takayuki Kondo6,7.   

Abstract

Myasthenia gravis (MG) is occasionally associated with autoimmune diseases in the central nervous system (CNS), such as neuromyelitis optica spectrum disorder (NMOSD), multiple sclerosis (MS), Morvan syndrome, and anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis. Here, we report five original cases associated with autoimmune disorders in the CNS among 42 patients with MG in a single tertiary hospital in Japan (11.9%). In four of these five cases, the second disease developed when the preceding disease was unstable. Accurate diagnosis of the newly developing disease may be difficult in such cases, because some neurological symptoms can be seen in both disorders. This implies the great importance of recognizing the possible co-occurrence of MG and disorders in the CNS. In addition, a comprehensive review of the literature revealed distinct clinical characteristics depending on the associated disease in the CNS, including thymic pathology and temporal relationship between MG and associated CNS disorders. Notably, NMOSD usually develops after the onset of MG and thymectomy, in clear contrast to MS. Thymoma is highly prevalent among patients with Morvan syndrome, in contract to cases with NMOSD and MS. The analysis of clinical characteristics, representing the first such investigation to the best of our knowledge, suggests different pathogeneses of these autoimmune diseases in the CNS, and provides significant implications for clinical practice.

Entities:  

Keywords:  Anti-N-methyl-D-aspartate receptor (NMDAR) encephalitis; Morvan syndrome; Multiple sclerosis (MS); Myasthenia gravis (MG); Neuromyelitis optica spectrum disorder (NMOSD)

Mesh:

Year:  2019        PMID: 31342158     DOI: 10.1007/s00415-019-09461-3

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  82 in total

1.  Exacerbation of myasthenia gravis in a patient after interferon-beta treatment for chronic active hepatitis C.

Authors:  H Harada; A Tamaoka; Y Kohno; A Mochizuki; S Shoji
Journal:  J Neurol Sci       Date:  1999-06-01       Impact factor: 3.181

2.  Onset of myasthenia gravis in a patient with multiple sclerosis during interferon-1b treatment.

Authors:  G Blake; S Murphy
Journal:  Neurology       Date:  1997-12       Impact factor: 9.910

Review 3.  Neuromyelitis optica spectrum disorders in patients with myasthenia gravis: ten new aquaporin-4 antibody positive cases and a review of the literature.

Authors:  S Jarius; F Paul; D Franciotta; J de Seze; C Münch; M Salvetti; K Ruprecht; M Liebetrau; K P Wandinger; G Akman-Demir; A Melms; W Kristoferitsch; B Wildemann
Journal:  Mult Scler       Date:  2011-12-19       Impact factor: 6.312

4.  Multiple paraneoplastic diseases occurring in the same patient after thymomectomy.

Authors:  C Briani; A Cagnin; S Blandamura; G Altavilla
Journal:  J Neurooncol       Date:  2010-02-10       Impact factor: 4.130

5.  Myasthenia gravis and multiple sclerosis.

Authors:  R A Shakir; J M Hussien; J V Trontelj
Journal:  J Neuroimmunol       Date:  1983-06       Impact factor: 3.478

6.  Clinical features and impact of myasthenia gravis disease in Australian patients.

Authors:  Stefan Blum; David Lee; David Gillis; David F McEniery; Stephen Reddel; Pamela McCombe
Journal:  J Clin Neurosci       Date:  2015-05-26       Impact factor: 1.961

7.  Systemic lupus erythematosus related recurrent transverse myelitis in a patient with myasthenia gravis and multiple sclerosis.

Authors:  M R Tola; I Casetta; E Granieri; L M Caniatti; V C Monetti; R Pascarella
Journal:  Eur Neurol       Date:  1996       Impact factor: 1.710

Review 8.  [A case of subacute myelitis with anti-aquaporin 4 antibody after thymectomy for myasthenia gravis: review of autoimmune diseases after thymectomy].

Authors:  Masayuki Kohsaka; Masami Tanaka; Masayuki Tahara; Yasukiyo Araki; Satoru Mori; Teturo Konishi
Journal:  Rinsho Shinkeigaku       Date:  2010-02

9.  Myasthenia gravis in Ceará, Brazil: clinical and epidemiological aspects.

Authors:  Aline de Almeida Xavier Aguiar; André Ferrer Carvalho; Carlos Mauricio de Castro Costa; José Marcelino Aragão Fernandes; José Artur Costa D'Almeida; Luís Edmundo Teixeira de Arruda Furtado; Francisco Marcos Bezerra da Cunha
Journal:  Arq Neuropsiquiatr       Date:  2010-12       Impact factor: 1.420

Review 10.  Japanese cases of neuromyelitis optica spectrum disorder associated with myasthenia gravis and a review of the literature.

Authors:  Ryotaro Ikeguchi; Yuko Shimizu; Shigeaki Suzuki; Satoru Shimizu; Chiaki Kabasawa; Shiori Hashimoto; Masayuki Masuda; Yuriko Nagane; Kimiaki Utsugisawa; Yasushi Suzuki; Toshiyuki Takahashi; Hiroya Utsumi; Kazuo Fujihara; Norihiro Suzuki; Shinichiro Uchiyama
Journal:  Clin Neurol Neurosurg       Date:  2014-08-20       Impact factor: 1.876

View more
  2 in total

Review 1.  Cross-syndrome: myasthenia gravis and the demyelinating diseases of the central nervous system combination. Systematic literature review and case reports.

Authors:  Ekaterina Luzanova; Svetlana Stepanova; Nikita Nadtochiy; Elena Kryukova; Maria Karpova
Journal:  Acta Neurol Belg       Date:  2022-06-14       Impact factor: 2.396

2.  Thymic Involution and Altered Naive CD4 T Cell Homeostasis in Neuromyelitis Optica Spectrum Disorder.

Authors:  Haoxiao Chang; Hengri Cong; Huabing Wang; Li Du; De-Cai Tian; Yuetao Ma; Yun Xu; Yupeng Wang; Linlin Yin; Xinghu Zhang
Journal:  Front Immunol       Date:  2021-07-16       Impact factor: 7.561

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.